Reading time: 4 minutes Susy Prieto Huarcaya, PhD For families facing diffuse midline glioma, time often feels painfully short and options even shorter. That’s why the FDA’s approval of dordaviprone (Modeyso™) marks a historic turning point—the first therapy for gliomas carrying the H3K27M mutation.  What Are Diffuse Midline Gliomas? Diffuse midline glioma (DMG) is a... Continue Reading →